Synergistic cannabinoid esters, their salts and uses thereof
AssigneeLondon Pharmaceuticals and Research Corporation
InventorMahmoud Mohamed Abdrabo Moustafa
Life of this patent
Estimating the term…
Abstract
Cannabinoid esters and their soluble salts with synergistic or additive therapeutic counterparts and stable formulations thereof, as well as their edible, beverage and medicinal applications. The synergistic or additive cannabinoid esters may be used as drugs or prodrugs for treating various conditions related to the modulation or biased modulation of cannabinoid receptors, including but not limited to, pain and inflammation, arthritis, cancer, glaucoma, neurodegenerative disorders, multiple sclerosis, renal fibrosis, fibrotic disorder, mental health disorders, addiction, motor function disorders and gastrointestinal and metabolic disorders.
Claims126
A cannabinoid compound, comprising a labile ester of a cannabinoid with a synergistic or additive therapeutic counterpart.
The cannabinoid compound of claim 76, wherein the cannabinoid compound is a compound of formula 61:
- wherein B is the therapeutic counterpart. 10 78. The cannabinoid of claim 77, wherein the therapeutic counterpart is selected from the group consisting of:
- glucosamine, psilocin, pregabalin, gabapentin, topiramate, morphine, levodopa, and citalopram.
A pharmaceutical formulation comprising a labile ester of a cannabinoid with a first synergistic or additive therapeutic counterpart and a second active ingredient having a synergistic or additive effect with the cannabinoid.
A method of producing a cannabinoid compound, the cannabinoid compound comprising a labile ester of a cannabinoid with a synergistic or additive therapeutic counterpart, comprising the step of:
- mixing a cannabinoid ester salt having a labile counter ion with the therapeutic counterpart in the form of a base, wherein the mixing step takes place in the presence of an aqueous solvent.
Dependencies are inferred from the claim text.